| __timestamp | Amphastar Pharmaceuticals, Inc. | Veracyte, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 40786000 |
| Thursday, January 1, 2015 | 46974000 | 47876000 |
| Friday, January 1, 2016 | 47298000 | 52035000 |
| Sunday, January 1, 2017 | 50918000 | 55348000 |
| Monday, January 1, 2018 | 58044000 | 65276000 |
| Tuesday, January 1, 2019 | 63109000 | 82720000 |
| Wednesday, January 1, 2020 | 65157000 | 89118000 |
| Friday, January 1, 2021 | 68920000 | 181193000 |
| Saturday, January 1, 2022 | 66592000 | 174078000 |
| Sunday, January 1, 2023 | 80393000 | 184232000 |
In pursuit of knowledge
In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Veracyte, Inc. and Amphastar Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, Veracyte's SG&A expenses surged by approximately 350%, reflecting its aggressive growth and expansion strategies. In contrast, Amphastar's expenses increased by about 100%, indicating a more conservative approach. Notably, in 2023, Veracyte's SG&A expenses were more than double those of Amphastar, highlighting its significant investment in marketing and administrative capabilities. This trend underscores the differing strategic priorities of these companies, with Veracyte focusing on rapid market penetration and Amphastar maintaining steady growth. As the industry evolves, these financial decisions will play a pivotal role in shaping their future trajectories.
Selling, General, and Administrative Costs: AbbVie Inc. vs Veracyte, Inc.
Merck & Co., Inc. and Veracyte, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Walgreens Boots Alliance, Inc. and Veracyte, Inc.
SG&A Efficiency Analysis: Comparing Jazz Pharmaceuticals plc and Amphastar Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Veracyte, Inc. and HUTCHMED (China) Limited
R&D Spending Showdown: Veracyte, Inc. vs Amphastar Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Veracyte, Inc. and Travere Therapeutics, Inc.
Veracyte, Inc. or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for MorphoSys AG and Amphastar Pharmaceuticals, Inc.
Comparing SG&A Expenses: HUTCHMED (China) Limited vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Comparing SG&A Expenses: Supernus Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Amphastar Pharmaceuticals, Inc. or Taro Pharmaceutical Industries Ltd.